These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 27004544)

  • 21. Epoprostenol for very low birth weight (VLBW) infants: a novel dilution protocol.
    Rugolotto S; Beghini R; Cogo I; Sidoti G; Padovani EM; Pietrobelli A
    Pediatr Med Chir; 2013; 35(5):223-4. PubMed ID: 24516943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
    Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
    J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful transition from intravenous to inhaled prostacyclin in a patient with pulmonary hypertension and right ventricular failure.
    Reddy MT; Patel H; Ventura HO
    Congest Heart Fail; 2008; 14(5):285-6. PubMed ID: 18983294
    [No Abstract]   [Full Text] [Related]  

  • 24. The globalization of clinical trials in pulmonary arterial hypertension.
    Park MH; Rubin LJ
    J Heart Lung Transplant; 2010 Feb; 29(2):157-8. PubMed ID: 20113908
    [No Abstract]   [Full Text] [Related]  

  • 25. Successful epoprostenol withdrawal in pulmonary arterial hypertension: case report and literature review.
    Demerouti EA; Manginas AN; Athanassopoulos GD; Karatasakis GT; Leontiadis ED; Pavlides GS
    Respir Care; 2013 Feb; 58(2):e1-5. PubMed ID: 22710078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
    J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapeutic management of primary pulmonary hypertension].
    Chaouat A; Weitzenblum E
    Presse Med; 2002 Feb; 31(7):320-8. PubMed ID: 11899690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations.
    Mathier MA; McDevitt S; Saggar R
    J Heart Lung Transplant; 2010 Nov; 29(11):1210-7. PubMed ID: 20855220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral prostacyclin therapy for pulmonary arterial hypertension: another step forward.
    Waxman AB
    Circulation; 2013 Feb; 127(5):563-5. PubMed ID: 23307828
    [No Abstract]   [Full Text] [Related]  

  • 30. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension.
    Minai OA; Parambil J; Dweik RA; Davila GH; Peterson L; Rollins KD; Chen H
    Respir Med; 2013 Mar; 107(3):458-65. PubMed ID: 23266038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulmonary hypertension complicating pulmonary fibrosis: bad and ugly, but good to treat?
    Nathan SD
    Thorax; 2014 Feb; 69(2):107-8. PubMed ID: 24431094
    [No Abstract]   [Full Text] [Related]  

  • 32. [Pharmacological and clinical profile of treprostinil (TREPROST® for injection)].
    Saito R; Ohmori Y
    Nihon Yakurigaku Zasshi; 2016 Jan; 147(1):56-62. PubMed ID: 26753860
    [No Abstract]   [Full Text] [Related]  

  • 33. Long-term treprostinil in pulmonary arterial hypertension: Is the glass half full or half empty?
    Provencher S
    Eur Respir J; 2006 Dec; 28(6):1073-5. PubMed ID: 17138674
    [No Abstract]   [Full Text] [Related]  

  • 34. Pulmonary arterial hypertension: classification and therapy with a focus on prostaglandin analogs.
    Papierniak ES; Lowenthal DT; Mubarak K
    Am J Ther; 2012 Jul; 19(4):300-14. PubMed ID: 21642835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Current status and future prospect of prostacyclin therapy for pulmonary hypertension--intravenous, subcutaneous, inhaled and oral PGI2 derivatives].
    Saji T; Nakayama T; Ishikita T; Matsuura H
    Nihon Rinsho; 2001 Jun; 59(6):1132-8. PubMed ID: 11411125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pulmonary arterial hypertension. New therapeutic principles improve treatment of a rare condition].
    Ekmehag B
    Lakartidningen; 2009 Aug 19-25; 106(34):2057-61. PubMed ID: 19769147
    [No Abstract]   [Full Text] [Related]  

  • 37. [Primary pulmonary hypertension. Treatment with prostacyclin I2 (epoprostenol)].
    Vicente R; Ramos F; Morales P
    Rev Esp Anestesiol Reanim; 1999; 46(6):274. PubMed ID: 10439652
    [No Abstract]   [Full Text] [Related]  

  • 38. Treprostinil to reverse pulmonary hypertension associated with idiopathic pulmonary fibrosis as a bridge to single-lung transplantation.
    Saggar R; Shapiro SS; Ross DJ; Fishbein MC; Zisman DA; Lynch JP; Weigt SS; Ardehali A; Belperio JA; Saggar R
    J Heart Lung Transplant; 2009 Sep; 28(9):964-7. PubMed ID: 19716051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulmonary hypertension update.
    Hesselgrave B
    Case Manager; 2005; 16(6):61-6; quiz 67. PubMed ID: 16326325
    [No Abstract]   [Full Text] [Related]  

  • 40. Intravenous and inhaled epoprostenol for primary pulmonary hypertension during pregnancy and delivery.
    Bildirici I; Shumway JB
    Obstet Gynecol; 2004 May; 103(5 Pt 2):1102-5. PubMed ID: 15121623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.